Investing in Amgen Inc. (AMGN)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)103.82-61
Intrinsic value (DCF)115.97-57
Graham-Dodd Method48.30-82
Graham Formula185.48-31

Products and Services

  • Biologics: Develops and produces innovative biologic treatments for various conditions, including cancer, kidney disease, and rheumatoid arthritis.
  • Biosimilars: Focuses on the development of biosimilars, offering cost-effective alternatives to existing biologic therapies.
  • Research and Development: Invests heavily in R&D to discover and develop novel therapies for serious illnesses.

SWOT Analysis


  • Innovation Leadership: Pioneer in biotechnology with a strong pipeline of innovative therapies.
  • Strong Financials: Robust financial performance with high revenue generation and investment in R&D.


  • Dependency on Key Products: Reliance on a small number of products for the majority of revenue, posing risks if patents expire or if sales decline.
  • Regulatory Challenges: Faces regulatory hurdles that can delay product approvals and impact market access.


  • Market Expansion: Potential for growth in emerging markets and expansion of existing treatments into new therapeutic areas.
  • Collaborations and Acquisitions: Opportunities to enhance the product pipeline through strategic partnerships and acquisitions.


  • Competitive Pressure: Intense competition in the biopharmaceutical sector, including from biosimilars and generic drugs.
  • Regulatory and Pricing Pressure: Global regulatory scrutiny and pressure to lower drug prices could affect profitability.


  • Summary: Amgen's strategic position as a leader in biotechnology and its focus on innovative and biosimilar products provide a solid foundation for growth. Navigating the challenges of product dependency and regulatory landscapes, alongside leveraging opportunities for market expansion and strategic collaborations, will be crucial for its future success.

Investment Analysis

  • Market Performance: Amgen's stock has demonstrated resilience, reflecting the market's confidence in its growth trajectory and innovative portfolio.
  • Revenue Streams: Diversification through biosimilars and new therapeutic areas presents a stable financial outlook.
  • Investor Sentiment: Positive investor sentiment bolstered by Amgen's commitment to innovation and strategic market expansions.
  • Future Outlook: Focused investments in R&D and strategic initiatives are expected to drive Amgen's long-term growth and profitability.

Company description

AMGN, or Amgen Inc., is a biotechnology company founded in 1980 and headquartered in California. The company focuses on the development and manufacturing of innovative therapies for serious illnesses, including cancer, cardiovascular diseases, and neurological disorders. With a team of over 23,000 employees worldwide, Amgen has a global presence and is dedicated to improving patients' lives by delivering transformative medicines. AMGN is highly recognized for its cutting-edge research and development efforts, with a strong portfolio of marketed products and a robust pipeline of potential treatments. The company has a strong financial standing, with consistent revenue growth and a commitment to investing in key areas of innovation. Additionally, AMGN has a strong corporate social responsibility program, aiming to make a positive impact on the environment, local communities, and the patients they serve. In summary, Amgen is a leading biotechnology company with a driven mission to advance medicine and improve healthcare outcomes for patients around the world.